Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma

Histology and Histopathology

Volumn 28, Issue 9, 2013, Pages 1217-1222

  Li, Guorong ^a   Badin, Grégory ^a   Zhao, An ^a   Gentil Perret, Anne ^a   Tostain, Jacques ^a   Péoc'h, Michel ^a   Gigante, Marc ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

Author keywords

CXCR4; Immunohistochemistry; Prognosis; Renal cell carcinoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, CXCR4; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884359062     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Coppin C., Kollmannsberger C., Le L., Porzsolt F. and Wilt T.J. (2011). Targeted therapy for advanced renal cell cancer (RCC): A cochrane systematic review of published randomised trials. BJU Int. 108, 1556-1563.
2. D'Alterio C., Consales C., Polimeno M., Franco R., Cindolo L., Portella L., Cioffi M., Calemma R., Marra L., Claudio L., Perdona S., Pignata S., Facchini G., Carteni G., Longo N., Pucci L., Ottaiano A., Costantini S., Castello G. and Scala S. (2010). Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr. Cancer Drug Targets 10, 772-781.
3. Edge S.B., Byrd D.R. and Compton C.C. (2010). AJCC cancer staging manual. 7th ed. Springer. New York, NY. pp 479-489.
4. Fuhrman S.A., Lasky L.C. and Limas C. (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655-663.
5. Furusato B., Mohamed A., Uhlen M. and Rhim J.S. (2010). CXCR4 and cancer. Pathol. Int. 60, 497-505.
6. Gahan J.C., Gosalbez M., Yates T., Young E.E., Escudero D.O., Chi A., Garcia-Roig M., Satyanarayana R., Soloway M.S., Bird V.G. and Lokeshwar V.B. (2012). Chemokine and chemokine receptor expression in kidney tumors: Molecular profiling of histological subtypes and association with metastasis. J. Urol. 187, 827-833.
7. Haviv Y.S., van Houdt W.J., Lu B., Curiel D.T. and Zhu Z.B. (2004). Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter. Mol. Cancer Ther. 3, 687-691.
8. Jones J., Marian D., Weich E., Engl T., Wedel S., Relja B., Jonas D. and Blaheta R.A. (2007). CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp. Cell. Res. 313, 4051-4065.
9. Kim S.P., Weight C.J., Leibovich B.C., Thompson R.H., Costello B.A., Cheville J.C., Lohse C.M. and Boorjian S.A. (2011). Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 78, 1101-1106.
10. Lam J.S., Leppert J.T., Figlin R.A. and Belldegrun A.S. (2005). Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66, 1-9.
11. Li G., Barthelemy A., Feng G., Gentil-Perret A., Peoc'h M., Genin C. and Tostain J. (2007). S100A1: A powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Histopathology 50, 642-647.
12. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S.T., Chen I., Huang X. and Figlin R.A. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590.
13. Pan J., Mestas J., Burdick M.D., Phillips R.J., Thomas G.V., Reckamp K., Belperio J.A. and Strieter R.M. (2006). Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol. Cancer 5, 56.
14. Richard C.L. and Blay J. (2008). CXCR4 in cancer and its regulation by PPARgamma. PPAR Res. 2008, 769413.
15. Sandlund J., Oosterwijk E., Grankvist K., Oosterwijk-Wakka J., Ljungberg B. and Rasmuson T. (2007). Prognostic impact of carbonic anhydrase ix expression in human renal cell carcinoma. BJU Int. 100, 556-560.
16. Schrader A.J., Lechner O., Templin M., Dittmar K.E., Machtens S., Mengel M., Probst-Kepper M., Franzke A., Wollensak T., Gatzlaff P., Atzpodien J., Buer J. and Lauber J. (2002). CXCR4/CXCL12 expression and signalling in kidney cancer. Br. J. Cancer 86, 1250-1256.
17. Spano J.P., Andre F., Morat L., Sabatier L., Besse B., Combadiere C., Deterre P., Martin A., Azorin J., Valeyre D., Khayat D., Le Chevalier T. and Soria J.C. (2004). Chemokine receptor CXCR4 and earlystage non-small cell lung cancer: Pattern of expression and correlation with outcome. Ann. Oncol. 15, 613-617.
18. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J. and Krek W. (2003). Chemokine receptor CXCR4 downregulated by von hippellindau tumour suppressor pVHL. Nature 425, 307-311.
19. Wang L., Yang B., Yang Q., Qiao S., Wang Y. and Sun Y. (2009). Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin. Exp. Metastasis 26, 1049-1054.
20. Wehler T.C., Graf C., Biesterfeld S., Brenner W., Schadt J., Gockel I., Berger M.R., Thuroff J.W., Galle P.R., Moehler M. and Schimanski C.C. (2008). Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J. Oncol. 2008, 626-340.
21. Zagzag D., Krishnamachary B., Yee H., Okuyama H., Chiriboga L., Ali M.A., Melamed J. and Semenza G.L. (2005). Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: Von hippel-lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65, 6178-6188.